{"filing":{"accession_number":"0001193125-26-398561","cik":"0001088856","ticker":"CORT","company_name":"CORCEPT THERAPEUTICS INC","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-22","primary_document":"d148256d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/d148256d8k.htm"},"events":[{"id":34495,"run_id":31741,"accession_number":"0001193125-26-398561","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Sean Maduck, President of Corcept Endocrinology, resigned effective October 1, 2026, after 14 years with the company. The filing also discloses a consulting arrangement and continued vesting of stock options as ancillary arrangements tied to the resignation.","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38235,"accession_number":"0001193125-26-398561","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Sean Maduck, President of Corcept Endocrinology, resigned effective October 1, 2026, after 14 years with the company. While the filing also discloses a consulting arrangement and the appointment of Justin Gunn as his successor, the principal disclosed action is Maduck's departure. The consulting agreement and continued vesting of stock options are ancillary arrangements tied to the resignation. The departure of a division president is material to investors assessing leadership continuity and operational stability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:16:54.712327+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":34496,"run_id":31741,"accession_number":"0001193125-26-398561","anchor_item_number":"7.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Justin Gunn was appointed as President of the Endocrinology division, effective October 1, 2026, with a reporting line to the CEO and membership on the Executive Team.","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38236,"accession_number":"0001193125-26-398561","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Justin Gunn as President of the Endocrinology division, effective October 1, 2026, with a reporting line to the CEO and membership on the Executive Team. While the press release also mentions Sean Maduck's retirement, the principal action disclosed is Gunn's appointment to a senior executive role. The appointment is material as it affects leadership of a major business division at a commercial-stage pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:16:54.712327+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38235,"accession_number":"0001193125-26-398561","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Sean Maduck, President of Corcept Endocrinology, resigned effective October 1, 2026, after 14 years with the company. While the filing also discloses a consulting arrangement and the appointment of Justin Gunn as his successor, the principal disclosed action is Maduck's departure. The consulting agreement and continued vesting of stock options are ancillary arrangements tied to the resignation. The departure of a division president is material to investors assessing leadership continuity and operational stability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:16:54.712327+00:00","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-09-23"},{"id":38236,"accession_number":"0001193125-26-398561","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Justin Gunn as President of the Endocrinology division, effective October 1, 2026, with a reporting line to the CEO and membership on the Executive Team. While the press release also mentions Sean Maduck's retirement, the principal action disclosed is Gunn's appointment to a senior executive role. The appointment is material as it affects leadership of a major business division at a commercial-stage pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:16:54.712327+00:00","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-09-23"}]}